Background illustration for clinical trials search

Merck Clinical Trials

Find clinical trials for Merck. Search for Merck clinical trials in different cities and states across the United States.

Filter

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

for
Non-small Cell Lung Cancer
Location: Westbrook ME, Farmington CT, Stamford CT, Hackensack NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07190248

Phase 3, Recruiting

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

for
Radiographic Axial Spondyloarthritis
Location: Quebec, Trois-Rivieres, Philadelphia PA, Baltimore MD,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 70+

Code: NCT07133633

Phase 2, Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

for
Malignant Neoplasm
Location: Boston MA, Valhalla NY, New York NY, New Brunswick NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT07630974

Phase 1, Phase 2, Recruiting

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

for
Malignant Neoplasm
Location: Montreal, Toronto, St Louis MO, San Antonio TX
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07600749

Phase 1, Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

for
Follicular Lymphoma
Location: Hackensack NJ, Durham NC, Lexington KY, Nashville TN,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07634471

Phase 2, Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

for
Metastatic Neoplasm
Location: Hackensack NJ, Chicago IL, Houston TX
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07030712

Phase 1, Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for
Prostate Cancer Metastatic
Location: New Haven CT, Quebec, The Bronx NY, Morristown NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136624

Phase 3, Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for
Colon Adenocarcinoma, Rectal Adenocarcinoma
Location: Moncton, Chicoutimi, New York NY, Hackensack NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06997497

Phase 3, Recruiting

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

for
Heterozygous Familial Hypercholesterolemia (HeFH)
Location: Boston MA, Wilmington DE, Washington D.C. DC,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 6 - 17

Code: NCT07058077

Phase 2, Phase 3, Recruiting

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

for
Colitis Ulcerative, Ulcerative Colitis
Location: Montreal, Miami FL, Toronto, Orlando FL, Inverness FL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 70+

Code: NCT07463183

Phase 2, Recruiting

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

for
Carcinoma, Non-Small-Cell Lung
Location: Baltimore MD, Pittsburgh PA, Lexington KY
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780085

Phase 2, Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

for
Early Alzheimer's Disease
Location: Newton MA, New Haven CT, Queens NY, Toms River NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 50 - 70+

Code: NCT07033494

Phase 2, Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

for
Advanced Solid Tumors, Malignant Neoplasm
Location: Hackensack NJ, Richmond VA, Miami FL, Birmingham AL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06818643

Phase 1, Phase 2, Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

for
Lung Neoplasm
Location: Baltimore MD, Fairfax VA, Lexington KY, Dallas TX
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780098

Phase 2, Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for
Malignant Neoplasm
Location: Boston MA, New Haven CT, Valhalla NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT06941272

Phase 1, Phase 2, Recruiting

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

for
Healthy, Hepatic Impairment
Location: Miami FL, Orlando FL, San Antonio TX
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Sex: All

Age: 18 - 70+

Code: NCT06997276

Phase 1, Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

for
Malignant Neoplasm
Location: Sherbrooke, New York NY, Hackensack NJ, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06979596

Phase 2, Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

for
Malignant Melanoma
Location: Hackensack NJ, Fairfax VA, Toronto, Brampton,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06961006

Phase 2, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: St. John's, Westbrook ME, Boston MA, Quebec, Sherbrooke,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06966700

Phase 3, Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

for
Renal Cell Carcinoma
Location: Mineola NY, New York NY, Durham NC, Pittsburgh PA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 70+

Code: NCT07049926

Phase 1, Phase 2, Recruiting